antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-5-6-39-60antibiotics-928Research ArticleОБЗОРЫREVIEWSОболочечные вирусы — патогенетическая мишень лектинов цианобактерийEnveloped Viruses: Pathogenetic Targets for Cyanobacterial Lectinshttps://orcid.org/0000-0002-2760-9778БЕСЕДНОВАН. Н.BESEDNOVAN. N.

Беседнова Наталия Николаевна — д. м. н., профессор, академик РАН, главный научный сотрудник лаборатории иммунологии.eLIBRARY SPIN-код: 8931-9002Scopus Author ID: 7006805123

690087, г. Владивосток, ул. Сельская, д. 1

Natalia N. Besednova — D. Sc. in medicine, Professor, Academician of the Russian Academy of Sciences.eLIBRARY SPIN: 8931-9002Scopus Author ID: 7006805123

690087, Vladivostok, Selskaya st., 1

besednoff_lev@mail.ruhttps://orcid.org/0000-0003-4456-808XАНДРЮКОВБ. Г.ANDRYUKOVB. G.

Андрюков Борис Георгиевич — д. м. н, ведущий научный сотрудник лаборатории молекулярной микробиологии ФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» Роспотребнадзора.ResearcherID: J-3752-2018eLIBRARY SPIN-код: 7757-3838Scopus Author ID: 57191370698

Владивосток

Boris G. Andryukov — D. Sc. in medicine, G. P. Somov Research Institute of Epidemiology and Microbiology of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. ResearcherID: J-3752-2018eLIBRARY SPIN: 7757-3838Scopus Author ID: 57191370698

Vladivostok

https://orcid.org/0000-0002-2760-9778ЗАПОРОЖЕЦТ. С.ZAPOROZHETST. S.

Запорожец Татьяна Станиславовна — д. м. н., главный научный сотрудник лаборатории иммунологии. ResearcherID: Y-9425-2018eLIBRARY SPIN-код: 8931-9002Scopus Author ID: 7006805123 

Владивосток

Tatyana S. Zaporozhets — D. Sc. in medicine. ResearcherID: Y-9425-2018eLIBRARY SPIN: 8931-9002Scopus Author ID: 7006805123

Vladivostok

ЕРМАКОВАС. П.ERMAKOVAS. P.

Ермакова Светлана Павловна — д. х. н., главный научный сотрудник лаборатории химии ферментов.

Владивосток

Svetlana P. Ermakova — D. Sc. in chemistry.

Vladivostok

https://orcid.org/0000-0002-4315-6959КУЗНЕЦОВАТ. А.KUZNETSOVAT. A.

Кузнецова Татьяна Алексеевна — д. м. н., главный научный сотрудник лаборатории иммунологии. ResearcherID: I-8399-2018eLIBRARY SPIN-код: 2359-1132Scopus Author ID: 7202571979

Владивосток

Tatyana A. Kuznetsova — D. Sc. in medicine. ResearcherID: I-8399-2018eLIBRARY SPIN: 2359-1132Scopus Author ID: 7202571979

Vladivostok

КРЫЖАНОВСКИЙС. П.KRYZHANOVSKYS. P.

Крыжановский Сергей Петрович — д. м. н., ученый секретарь.

Владивосток

Sergey P. Kryzhanovsky — D. Sc. in medicine.

Vladivostok

https://orcid.org/0000-0001-8610-7623ЩЕЛКАНОВМ. Ю.SHCHELKANOVM. Y.

Щелканов Михаил Юрьевич — д. б. н., директор «ФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» Роспотребнадзора; заведующий лабораторией вирусологии ФГБУН «Федеральный научный Центр биоразнообразия наземной биоты Восточной Азии» ДВО РАН; ведущий научный сотрудник ФГБУН «Национальный научный Центр морской биологии» ДВО РАН. ResearcherID: L-6164-2016eLIBRARY SPIN-код: 5736-7230Scopus Author ID: 7004251692. 

Владивосток

Mikhail Yu. Shchelkanov — D. Sc. in biology, G. P. Somov Research Institute of Epidemiology and Microbiology of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Federal Scientific Center of the Eastern Asia Terrestrial Biodiversity, Far Eastern Branch of Russian Academy of Sciences.Researcher ID: L-6164-2016eLIBRARY SPIN: 5736- 7230Scopus Author ID: 7004251692.

Vladivostok

ФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» РоспотребнадзораРоссияSomov Research Institute of Epidemiology and Microbiology by Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian FederationФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» Роспотребнадзора; Дальневосточный федеральный университет (ДВФУ), Школа медициныРоссияSomov Research Institute of Epidemiology and Microbiology by Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Far Eastern Federal University (FEFU)Russian FederationТихоокеанский институт биоорганической химии им. Г. Б. Елякова ДВО РАН (ТИБОХ ДВО РАН)РоссияElyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of Russian Academy of SciencesRussian FederationМедицинское объединение ДВО РАНРоссияMedical Association of the Far Eastern Branch of the Russian Academy of SciencesRussian FederationФГБНУ «Научно-исследовательский институт эпидемиологии и микробиологии им. Г. П. Сомова» Роспотребнадзора; ФГБУН «Федеральный научный Центр биоразнообразия наземной биоты Восточной Азии» ДВО РАНРоссияSomov Research Institute of Epidemiology and Microbiology by Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Federal Scientific Center of the Eastern Asia Terrestrial Biodiversity, Far Eastern Branch of Russian Academy of SciencesRussian Federation202209092022675-63960Copyright © БЕСЕДНОВА Н.Н., АНДРЮКОВ Б.Г., ЗАПОРОЖЕЦ Т.С., ЕРМАКОВА С.П., КУЗНЕЦОВА Т.А., КРЫЖАНОВСКИЙ С.П., ЩЕЛКАНОВ М.Ю., 20222022БЕСЕДНОВА Н.Н., АНДРЮКОВ Б.Г., ЗАПОРОЖЕЦ Т.С., ЕРМАКОВА С.П., КУЗНЕЦОВА Т.А., КРЫЖАНОВСКИЙ С.П., ЩЕЛКАНОВ М.Ю.BESEDNOVA N.N., ANDRYUKOV B.G., ZAPOROZHETS T.S., ERMAKOVA S.P., KUZNETSOVA T.A., KRYZHANOVSKY S.P., SHCHELKANOV M.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/928

Лектины — группа углеводсвязывающих высокоспецифичных белков с широким спектром действия, участвующих в так называемой «первой линии» защиты организма. Эти уникальные биомолекулы проявляют высокую специфичность к различным моно- и олигосахаридам, в первую очередь, гликоконъюгатам вирусов и бактерий. Лектины цианобактерий эффективны против оболочечных вирусов и являются привлекательной альтернативой существующим синтетическим лекарственным препаратам. Известно практически полное отсутствие формирования резистентности у вирусов к этим соединениям. Цель обзора — анализ, обобщение и обсуждение результатов экспериментальных исследований in vivo и in vitro, иллюстрирующих механизмы действия и противовирусные эффекты лектинов, полученных из цианобактерий, в отношении наиболее опасных и социально значимых вирусов: SARS-Cov-2, ВИЧ, вирусов Эбола, гриппа и гепатита С. Кроме того, мы рассмотрим некоторые трудности, которые необходимо преодолеть для получения эффективных противовирусных препаратов в будущем.

Lectins are a group of highly specific carbohydrate-binding proteins with a wide spectrum of action, involved in the so-called «first line» of body defense. These unique biomolecules show high specificity for various mono- and oligosaccharides, primarily for viral and bacterial glycoconjugates. Cyanobacteria lectins are effective against enveloped viruses and are an appealing alternative to existing synthetic drugs. Virtually complete absence of resistance formation in viruses to these compounds is known. The purpose of this review is to analyze, summarize, and discuss the results of experimental studies in vivo and in vitro, illustrating the mechanisms of action and antiviral effects of lectins obtained from cyanobacteria in relation to the most dangerous and socially significant viruses: SARS-Cov-2, HIV, Ebola viruses, influenza, and hepatitis C. In addition, the article outlines some of the challenges that must be overcome in order to obtain effective antiviral drugs in the future.

цианобактерии (ЦБ)метаболитыоболочечные вирусылектинылечебные средствапрофилактические средстваcyanobacteria (CB)metabolitesenveloped viruseslectinstherapeutic agentsprophylactic agentsReferencesBabich O., Sukhikh S., Larina V. et al. Algae: study of edible and biologically active fractions, their properties and applications. Plants. 2022; 11 (6): 780. doi:10.3390/plants11060780.Babich O., Sukhikh S., Larina V. et al. Algae: study of edible and biologically active fractions, their properties and applications. Plants. 2022; 11 (6): 780. doi:10.3390/plants11060780.Barzkar N., Jahromi S.T., Poorsaheli H.B., Vianello F. Metabolites from marine microorganisms, micro, and macroalgae: immense scope for pharmacology. Mar. Drugs. 2019; 17 (8): 464. doi:10.3390/md17080464.Barzkar N., Jahromi S.T., Poorsaheli H.B., Vianello F. Metabolites from marine microorganisms, micro, and macroalgae: immense scope for pharmacology. Mar. Drugs. 2019; 17 (8): 464. doi:10.3390/md17080464.Schirrmeister B.E., Antonelli A., Bagheri H.C. The origin of multicellularity in cyanobacteria. Evol. Biol. 2011; 11: 45. doi:10.1186/1471-2148-11-45.Schirrmeister B.E., Antonelli A., Bagheri H.C. The origin of multicellularity in cyanobacteria. Evol. Biol. 2011; 11: 45. doi:10.1186/1471-2148-11-45.Tiwari A.K., Tiwari B.S. Cyanoterapeutics: an emerging field for future drug discovery. Applied Phicology. 2020; 1 (1): 44–57. https://doi.org/10.1080/26388081.2020.1744480.Tiwari A.K., Tiwari B.S. Cyanoterapeutics: an emerging field for future drug discovery. Applied Phicology. 2020; 1 (1): 44–57. https://doi.org/10.1080/26388081.2020.1744480.Ughy B., Nagy C.I., Kos P.B. Biomedical potential of cyanobacteria and algae. Acta Biologica Szegediensis. 2015; 59: 203–224.Ughy B., Nagy C.I., Kos P.B. Biomedical potential of cyanobacteria and algae. Acta Biologica Szegediensis. 2015; 59: 203–224.Shih P.M., Wu D., Latifi A. et al. Improving the coverage of the cyanobacterial phylum using diversity-driven genome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2013; 110: 1053–1058. doi:10.1073/pnas.1217107110.Shih P.M., Wu D., Latifi A. et al. Improving the coverage of the cyanobacterial phylum using diversity-driven genome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2013; 110: 1053–1058. doi:10.1073/pnas.1217107110.Uzair B., Tabassum S., Rasheed M., Rehman S.F. Exploring marine cyanobacteria for lead compounds of pharmaceutical importance. Revierw Article. Open Access. 2012; volume 2012. Article ID 179782. doi:10.1100/179782.Uzair B., Tabassum S., Rasheed M., Rehman S.F. Exploring marine cyanobacteria for lead compounds of pharmaceutical importance. Revierw Article. Open Access. 2012; volume 2012. Article ID 179782. doi:10.1100/179782.Stanier R.Y., Sistrom W.R., Hansen T.A. et al. Proposal to place the nomenclature of the Cyanobacteria (blue-green algae) under ther rules of the international code of nomenclature of bacteria. Int. J. Syst. Bacteriol. 1978; 28: 335–336.Stanier R.Y., Sistrom W.R., Hansen T.A. et al. Proposal to place the nomenclature of the Cyanobacteria (blue-green algae) under ther rules of the international code of nomenclature of bacteria. Int. J. Syst. Bacteriol. 1978; 28: 335–336.Walter J.M., Coutinho F.N., Dutilh B.E. et al. Ecogenomics and taxonomy of cyanjbacteria phylum. Front Microbiol. 2017. doi:10.3389/fmicb.2017.02132.Walter J.M., Coutinho F.N., Dutilh B.E. et al. Ecogenomics and taxonomy of cyanjbacteria phylum. Front Microbiol. 2017. doi:10.3389/fmicb.2017.02132.Tan L.T., Phyo M.Y. Marine Cyanobacteria: a source of lead compounds and their clinically relevant molecular targets. Molecules. 2020; 25 (9): 2197. doi:10.3390/molecules25092197.Tan L.T., Phyo M.Y. Marine Cyanobacteria: a source of lead compounds and their clinically relevant molecular targets. Molecules. 2020; 25 (9): 2197. doi:10.3390/molecules25092197.Jones M.R., Pinto E., Torres M.A. et al. CyanoMetDB, a comprehensive public database of secondary metabolites from cyanobacteria. Water Research. 2021; 196: 117017. doi:10.1016/j.watres.2021.117017.Jones M.R., Pinto E., Torres M.A. et al. CyanoMetDB, a comprehensive public database of secondary metabolites from cyanobacteria. Water Research. 2021; 196: 117017. doi:10.1016/j.watres.2021.117017.Demay J., Bernard C., Reinhardt A., Marie B. Natural products from cyanobacteria: focus on beneficial activities. Mar. Drugs. 2019; 17 (6): 320. doi:103390/md17060320.Demay J., Bernard C., Reinhardt A., Marie B. Natural products from cyanobacteria: focus on beneficial activities. Mar. Drugs. 2019; 17 (6): 320. doi:103390/md17060320.Singh R.S., Walia A.K., Singhhattar J. et al. Cyanobacterial lectins characteristics and their role as antiviral agents. Int. J. of Biological Macromolecules. 2017; 102: 475–496. doi:10.1016/j.biomac.2017.04.041.Singh R.S., Walia A.K., Singhhattar J. et al. Cyanobacterial lectins characteristics and their role as antiviral agents. Int. J. of Biological Macromolecules. 2017; 102: 475–496. doi:10.1016/j.biomac.2017.04.041.Mazur-Marzec H., Ceglowska M., Konkel R. Pyrc K. Antiviral cyanometabolites-a review. Biomolecules. 2021; 11 (3): 474. doi:10.3390/biom11030474.Mazur-Marzec H., Ceglowska M., Konkel R. Pyrc K. Antiviral cyanometabolites-a review. Biomolecules. 2021; 11 (3): 474. doi:10.3390/biom11030474.Fernandez-Romero J.A., Paglini M.G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar. Drugs. 2021; 19 (12): 687. doi:10.3390/md19120687.Fernandez-Romero J.A., Paglini M.G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar. Drugs. 2021; 19 (12): 687. doi:10.3390/md19120687.Maier I., Schiesti R.H., Kontaxis. Cyanovirin-N binds viral envelope proteins at the low-affinity carbohydrate binding site without direct virus neutralization ability. Molecules. 2021; 26 (12): 3621. doi:10.3390/molecules26123621.Maier I., Schiesti R.H., Kontaxis. Cyanovirin-N binds viral envelope proteins at the low-affinity carbohydrate binding site without direct virus neutralization ability. Molecules. 2021; 26 (12): 3621. doi:10.3390/molecules26123621.Matei E., Basu R., Furey W. et al. Structure and glycan binding of a new cyanovirin-N homolog. J. Biol. Chem. 2016; 291 (36): 18967–18976. doi:10.1074/jbc.M116.740415.Matei E., Basu R., Furey W. et al. Structure and glycan binding of a new cyanovirin-N homolog. J. Biol. Chem. 2016; 291 (36): 18967–18976. doi:10.1074/jbc.M116.740415.Subramaniyan Vijayakumar, Menakha M. Pharmaceutical applications of cyanobacteria- a review. J. of Acute Medicine. 2015; 6 (1): 15–23. doi:10.1016/j.jacme.2015.02.004.Subramaniyan Vijayakumar, Menakha M. Pharmaceutical applications of cyanobacteria- a review. J. of Acute Medicine. 2015; 6 (1): 15–23. doi:10.1016/j.jacme.2015.02.004.Щелканов М.Ю., Дедков В.Г., Галкина И.В., Магассуба Н’Ф., Зуманиги Н., Шипулин Г.А., Попова А.Ю., Малеев В.В. Районирование Африканской природноочаговой провинции в отношение филовирусных лихорадок. Вестник РАМН. 2017; 72 (5): 325–335. https://doi.org/10.15690/vramn804.Shchelkanov M.Yu., Dedkov V.G., Galkina I.V. et al. Zoning of the African natural focal province in relation to filovirus fevers. Vestnik RAMN. 2017; 72 (5): 325–335. https://doi.org/10.15690/vramn804. (in Russian)Shchelkanov M.Yu., Popova A.Yu., Dedkov V.G. et al. History of study and modern classification of coronaviruses (Nidovirales: Coronaviridae). Russian journal of Infection and Immunity. 2020 а; 10 (2): 221–246. (In Russ.). doi:10.15789/2220-7619-HOI-1412.Shchelkanov M.Yu., Popova A.Yu., Dedkov V.G. et al. History of study and modern classification of coronaviruses (Nidovirales: Coronaviridae). Russian journal of Infection and Immunity. 2020 а; 10 (2): 221–246. (In Russ.). doi:10.15789/2220-7619-HOI-1412.Lvov D.K., Shchelkanov M.Yu., Alkhovsky S.V. et al. Zoonotic viruses of Northern Eurasia. Taxonomy and Ecology. Academic Press, 2015. 452 p.Lvov D.K., Shchelkanov M.Yu., Alkhovsky S.V. et al. Zoonotic viruses of Northern Eurasia. Taxonomy and Ecology. Academic Press, 2015. 452 p.Trovato M., Sartorius R., D’Apice L. et al. Viral emerging diseases: challenges in developing vaccination strategies. Front. Immunol. 2020. doi:103389/fimmu.2020.02130.Trovato M., Sartorius R., D’Apice L. et al. Viral emerging diseases: challenges in developing vaccination strategies. Front. Immunol. 2020. doi:103389/fimmu.2020.02130.Pollard A.J., Bijker E.M. A guide tovaccinology: from basic principles to new developments. Nat. Rev. Immunol. 2021; 21: 83–100. doi:10.1038/s41577-020-00479-7.Pollard A.J., Bijker E.M. A guide tovaccinology: from basic principles to new developments. Nat. Rev. Immunol. 2021; 21: 83–100. doi:10.1038/s41577-020-00479-7.Reinolds D., Huesemann M. Viral inhibitors from macroalgae, microalgae, and cyanobacteria: a review of antiviral potential throughout pathogenesis. Algal Research. 2021; 57: 102331. doi:10.1016/j.algal.2021.102331.Reinolds D., Huesemann M. Viral inhibitors from macroalgae, microalgae, and cyanobacteria: a review of antiviral potential throughout pathogenesis. Algal Research. 2021; 57: 102331. doi:10.1016/j.algal.2021.102331.Щелканов М.Ю., Попова А.Ю., Дедков В.Г. и др. История изучения и современная классификация коронавирусов (Nidovirales: Coronaviridae). Инфекция и иммунитет. 2020; 10 (2): 221–246. https://doi.org/10.15789/2220-7619-HOI-1412.Shchelkanov M.Yu., Kolobukhina L.V., Burgasova O.A. et al. COVID-19: etiology, clinic, treatment). Russian Journal of Infection and Immunity. 2020; 10 (3): 421–445. https://doi.org/10.15789/2220-7619-HOI-1412. (in Russian)Shchelkanov M.Yu., Popova A.Yu., Dedkov V.G. History of study and modern classification of coronaviruses (Nidovirales: Coronaviridae). Russian journal of Infection and Immunity. 2020 а; 10 (2): 221–246 (In Russ.). doi:10.15789/2220-7619-HOI-1412.Shchelkanov M.Yu., Popova A.Yu., Dedkov V.G. History of study and modern classification of coronaviruses (Nidovirales: Coronaviridae). Russian journal of Infection and Immunity. 2020 а; 10 (2): 221–246 (In Russ.). doi:10.15789/2220-7619-HOI-1412.Щелканов М.Ю., Цыбульский А.В., Дедков В.Г., Галкина И.В., Малеев В.В. Антимикробные пептиды как перспективные средства терапии первичных вирусных пневмоний. Инфекция и иммунитет. 2021; 11 (5): 837–852. https://doi.org/10.15789/2220-7619-APA-1595.Shchelkanov M.Yu., Tsybulsky A.V., Dedkov V.G. et al. Antimicrobial peptides as promising agents for the treatment of primary viral pneumonia. Russian Journal of Infection and Immunity. 2021; 11 (5): 837–852. https://doi.org/10.15789/2220-7619-APA-1595. (in Russian)Andrew M., Jayaraman G. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona virus disease (COVID-19). Carbohydr Res. 2021; 505: 108326. doi:10.1016/j.carres.2021.108326Andrew M., Jayaraman G. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona virus disease (COVID-19). Carbohydr Res. 2021; 505: 108326. doi:10.1016/j.carres.2021.108326Щелканов М.Ю., Ананьев В.Ю., Кузнецов В.В., Шуматов В.Б. Ближневосточный респираторный синдром: когда вспыхнет тлеющий очаг? Тихоокеанский медицинский журнал. 2015; 2: 94–98.Shchelkanov M.Yu., Ananiev V.Yu., Kuznetsov V.V., Shumatov V.B. Middle East respiratory syndrome: when will the smoldering fire erupt? Tikhookeanskiy Meditsinskiy Zhurnal. 2015; (2): 94–98. (in Russian)Щелканов М.Ю., Ананьев В.Ю., Кузнецов В.В., Шуматов В.Б. Эпидемическая вспышка Ближневосточного респираторного синдрома в Республике Корея (май-июль 2015 г.): причины, динамика, выводы. Тихоокеанский медицинский журнал. 2015; 3: 25–29.Shchelkanov M.Yu., Ananiev V.Yu., Kuznetsov V.V. et al. Epidemic outbreak of the Middle East respiratory syndrome in the Republic of Korea (MayJuly 2015): causes, dynamics, conclusions. Tikhookeanskiy meditsinskiy zhurnal. 2015; 3: 25–29. (in Russian)Gribova V.V., Okun D.B., Shalfeeva E.A. et al. Cloud service for the differential clinical diagnostics of acute respiratory viral diseases (including those associated with highly contagious coronaviruses) with an application of methods of artificial intelligence. Yakut Medical Journal. 2020; (2): 44–47. doi:10.25789/YMJ.2020.70.13Gribova V.V., Okun D.B., Shalfeeva E.A. et al. Cloud service for the differential clinical diagnostics of acute respiratory viral diseases (including those associated with highly contagious coronaviruses) with an application of methods of artificial intelligence. Yakut Medical Journal. 2020; (2): 44–47. doi:10.25789/YMJ.2020.70.13Nikiforov V.V., Kolobukhina L.V., Smetanina S.V. et al. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. Toolkit. M.: Department of Health of Moscow, 2020. 71 p.Nikiforov V.V., Kolobukhina L.V., Smetanina S.V. et al. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. Toolkit. M.: Department of Health of Moscow, 2020. 71 p.Monteil V., Kwon H., Prado P. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181 (4): 905–913.e7. doi:10.1016/j.cell.2020.04.004.Monteil V., Kwon H., Prado P. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181 (4): 905–913.e7. doi:10.1016/j.cell.2020.04.004.Guide to virology. Viruses and viral infections of humans and animals / Ed.: D.K. Lvov. M.: MIA, 2013. 1200 p.Guide to virology. Viruses and viral infections of humans and animals / Ed.: D.K. Lvov. M.: MIA, 2013. 1200 p.Barre A., Van Damme E.J.M., Simplicien M. et al. Man-specific lectins from plants, fungi, algae and cyanobacteria, as potential blockers for SARS-COV, MERS-COV and SARS-COV2 (COVID-19) coronaviruses: biomedical perspectives. Cells. 2021; 10 (7): 1619. doi:10.3390/cells10071619.Barre A., Van Damme E.J.M., Simplicien M. et al. Man-specific lectins from plants, fungi, algae and cyanobacteria, as potential blockers for SARS-COV, MERS-COV and SARS-COV2 (COVID-19) coronaviruses: biomedical perspectives. Cells. 2021; 10 (7): 1619. doi:10.3390/cells10071619.Hoffman M., Zhang L., Kruger N. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports. doi:10.1016/j.celrep.2021.109017.Hoffman M., Zhang L., Kruger N. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports. doi:10.1016/j.celrep.2021.109017.Naidoo D., Kar P., Roy A. et al. Structural insight into the binding of cyanovirin-N with the spike glycoprotein, Mpro and PLpro of SARS-CoV-2: protein-protein interactions, dynamics simulations and free energy calculations. Molecules. 2021; 26 (17): 5114. doi:10.3390/molecules26175114.Naidoo D., Kar P., Roy A. et al. Structural insight into the binding of cyanovirin-N with the spike glycoprotein, Mpro and PLpro of SARS-CoV-2: protein-protein interactions, dynamics simulations and free energy calculations. Molecules. 2021; 26 (17): 5114. doi:10.3390/molecules26175114.O’Keefe B.R., Giomarelli B., Barnard D.L. et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffitsin against emerging viruses of the family Coronaviridae. J. Virol. 2010; 84 (5): 2511-2521. doi:10.1128/JVI.02322-09.O’Keefe B.R., Giomarelli B., Barnard D.L. et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffitsin against emerging viruses of the family Coronaviridae. J. Virol. 2010; 84 (5): 2511-2521. doi:10.1128/JVI.02322-09.Millet J.K., Seron K., Labitt R.N. et al. Middle east respiratory syndrome coronavirus infection is inhibited by griffitsin. Antiviral Res. 2016. 133: 1–8. doi:10.1016/j.antiviral.2016.07.011.Millet J.K., Seron K., Labitt R.N. et al. Middle east respiratory syndrome coronavirus infection is inhibited by griffitsin. Antiviral Res. 2016. 133: 1–8. doi:10.1016/j.antiviral.2016.07.011.Sami Neha, Rakhshan Ahmad, Fatma Tasneem et al. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARSCoV-2. Biomedical J., 2021; 44 (1): 54–62. doi:10.1016/j.bj.2020.11.014.Sami Neha, Rakhshan Ahmad, Fatma Tasneem et al. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARSCoV-2. Biomedical J., 2021; 44 (1): 54–62. doi:10.1016/j.bj.2020.11.014.Cai Y., Xu W., Gu X. et al. Griffitsin with a broad-spectrum antiviral activity by binding glycans in viral glycoprotein exhibits strong synergistic effect in combination with a pan-coronavirus fusion inhibitor targeting SARSCoV-2 spike S2 subunit. Virol. Sin. 2020; 35 (6): 857–860. doi:10.1007/s12250-020-00305-3.Cai Y., Xu W., Gu X. et al. Griffitsin with a broad-spectrum antiviral activity by binding glycans in viral glycoprotein exhibits strong synergistic effect in combination with a pan-coronavirus fusion inhibitor targeting SARSCoV-2 spike S2 subunit. Virol. Sin. 2020; 35 (6): 857–860. doi:10.1007/s12250-020-00305-3.Bhatt A., Arora P., Prajapati S.K. Can algal derived bioactive metabolites serve as potential therapeutics for the treatment of SARS-CoV-2 like viral infection? Front. Microbiol. 2020; 11: 596374. doi:10.3389/fmicb.2020.596374.Bhatt A., Arora P., Prajapati S.K. Can algal derived bioactive metabolites serve as potential therapeutics for the treatment of SARS-CoV-2 like viral infection? Front. Microbiol. 2020; 11: 596374. doi:10.3389/fmicb.2020.596374.Lvov D.K., Shchelkanov M.Yu., Prilipov A.G. et al. Evolution of HPAI H5N1 virus in Natural ecosystems of Northern Eurasia (2005–2008). Avian Diseases. 2010. 54 (1): 483–495. doi:10.1637/8893-042509-Review.1Lvov D.K., Shchelkanov M.Yu., Prilipov A.G. et al. Evolution of HPAI H5N1 virus in Natural ecosystems of Northern Eurasia (2005–2008). Avian Diseases. 2010. 54 (1): 483–495. doi:10.1637/8893-042509-Review.1Щелканов М.Ю., Колобухина Л.В., Львов Д.К. Грипп: история, клиника, патогенез. Лечащий врач. 2011; 10: 33–38.Shchelkanov M.Yu., Kolobukhina L.V., Lvov D.K. Influenza: history, clinic, pathogenesis. Lechashchiy Vrach. 2011; 10: 33–38. (in Russian)Львов Д.К., Прилипов А.Г., Щелканов М.Ю., Дерябин П.Г., Шилов А.А., Гребенникова Т.В., Садыкова Г.К., Ляпина О.В. Молекулярно-генетический анализ биологических свойств высокопатогенных штаммов вируса гриппа A/H5N1, изолированных от диких и домашних птиц в период эпизоотии в Западной Сибири (июль 2005 г.). Вопросы вирусологии. 2006; 51 (2): 15–19.Lvov D.K., Prilipov A.G., Shchelkanov M.Yu. et al. Molecular genetic analysis of the biological properties of highly pathogenic influenza A/H5N1 virus strains isolated from wild and domestic birds during an epizootic in Western Siberia (July 2005).Voprosy Virusologii. 2006; 51(2): 15–19. (in Russian)Щелканов М.Ю., Кириллов И.М., Шестопалов А.М., Литвин К.Е., Дерябин П.Г., Львов Д.К. Эволюция вируса гриппа А / H5N1 (1996–2016). Вопросы вирусологии. 2016; 61 (6): 245–256. https://doi.org/10.18821/0507-4088-2016-61-6-245-256.Shchelkanov M.Yu., Kirillov I.M., Shestopalov A.M. et al. Evolution of influenza A virus / H5N1 (1996-2016). Voprosy Virusologii. 2016; 61 (6): 245–256. https://doi.org/10.18821/0507-4088-2016-61-6-245-256. (in Russian)Львов Д.К., Щелканов М.Ю., Федякина И.Т., Дерябин П.Г., Прошина Е.С., Пономаренко Р.А. Штамм вируса гриппа А/IIV-Anadyr/177-ma/2009 (H1N1) pdm09, адаптированный к тканям легких лабораторных мышей. Патент Российской Федерации № 2487936. Приоритет изобретения 02.02.2012.Lvov D.K., Shchelkanov M.Yu., Fedyakina I.T. et al. Influenza virus strain А/IIV-Anadyr/177-ma/2009 (H1N1) pdm09, adapted to the tissues of the lungs of laboratory mice. Patent of the Russian Federation No. 2487936. Invention Priority 02.02.2012. (in Russian)Gulyaeva M., Sobolev I., Sharshov K., Kurskaya O. et al. Characterization of avian-like Influenza A (H4N6) virus isolated from Caspian seal in 2012. Virologica Sinica. 2018 ; 33 (5): 449–452. DOI:10.1007/s12250-018-0053-yGulyaeva M., Sobolev I., Sharshov K., Kurskaya O. et al. Characterization of avian-like Influenza A (H4N6) virus isolated from Caspian seal in 2012. Virologica Sinica. 2018 ; 33 (5): 449–452. DOI:10.1007/s12250-018-0053-yTong S., Li Y., Rivailler P., Conrardy C. et al. A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (11): 4269–4274.Tong S., Li Y., Rivailler P., Conrardy C. et al. A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (11): 4269–4274.Щелканов М.Ю., Львов Д.К. Новый субтип вируса гриппа А от летучих мышей и новые задачи эколого-вирусологического мониторинга. Вопросы вирусологии. 2012; (Приложение 1): 159–168.Shchelkanov M.Yu., Lvov D.K. New subtype of influenza A virus from bats and new tasks of ecological and virological monitoring. Voprosy Virusologii. 2012; (Supl. 1): 159–168. (in Russian)O’Keefe B.R., Smee D.F., Turpin J. et al. Potent anti-influenza activity of cyanovirin –N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003; 47 (8): 2518–2525.O’Keefe B.R., Smee D.F., Turpin J. et al. Potent anti-influenza activity of cyanovirin –N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003; 47 (8): 2518–2525.Щелканов М.Ю., Магассуба Н., Дедков В.Г. и др. Природный резервуар филовирусов и типы связанных с ними эпидемических вспышек на территории Африки. Вестник РАМН. 2017; 72 (2): 112–119. https://doi.org/10.15690/vramn803.Shchelkanov M.Yu., Magassuba N., Dedkov V.G. et al. Natural reservoir of filoviruses and types of epidemic outbreaks associated with them in Africa. Vestnik RAMN. 2017; 72 (2): 112–119. https://doi.org/10.15690/vramn803. (in Russian)Щелканов М.Ю., Дедков В.Г., Галкина И.В., Магассуба Н’Ф., Зуманиги Н., Шипулин Г.А., Попова А.Ю., Малеев В.В. Районирование Африканской природноочаговой провинции в отношение филовирусных лихорадок. Вестник РАМН. 2017; 72 (5): 325–335. https://doi.org/10.15690/vramn804.Shchelkanov M.Yu., Dedkov V.G., Galkina I.V. et al. Zoning of the African natural focal province in relation to filovirus fevers. Vestnik RAMN. 2017; 72 (5): 325–335. [Shchelkanov M.Yu., Dedkov V.G., Galkina I.V., et al. Zoning of the African natural focal province in relation to filovirus fevers. Vestnik RAMN. 2017; 72 (5): 325–335. (in Russian)] https://doi.org/10.15690/vramn804Щелканов М.Ю., Magassouba N’F., Boiro M.Y., Малеев В.В. Причины развития эпидемии лихорадки Эбола в Западной Африке. Лечащий врач. 2014; 11: 30–36.Shchelkanov M.Yu., Magassouba N.F., Boiro M.Y., Maleev V.V. Causes of the Ebola Epidemic in West Africa. Lechashchiy Vrach. 2014; 11: 30–36. (in Russian)Mariappan V., Pratheesh P., Shanmugam L. et al. Viral hemorrhagic fever: molecular pathogenesis and current trends of disease management – an update. Current research in virological science. 2021; 2: 100009. doi:10.1016/j.crivro.2021.100009.Mariappan V., Pratheesh P., Shanmugam L. et al. Viral hemorrhagic fever: molecular pathogenesis and current trends of disease management – an update. Current research in virological science. 2021; 2: 100009. doi:10.1016/j.crivro.2021.100009.Barrientos L.G., O’Keefe B.R., Bray M. et al. Cyanovirin-N binds to the viral surface glycoprotein GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58: 47–56. doi:10.1016/s0166-3542(02)00183-3Barrientos L.G., O’Keefe B.R., Bray M. et al. Cyanovirin-N binds to the viral surface glycoprotein GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003; 58: 47–56. doi:10.1016/s0166-3542(02)00183-3Barrientos L.G., Lasala F., Otero J.R. et al. In vivo evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors with Filovirus envelope glycoproteins. J. of Infectious Diseases. 2004; 189 (8): 1440–1443. doi:10.1086/382658Barrientos L.G., Lasala F., Otero J.R. et al. In vivo evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors with Filovirus envelope glycoproteins. J. of Infectious Diseases. 2004; 189 (8): 1440–1443. doi:10.1086/382658Garrison A.R., Giomarelli B.G., Lear-Rooney C.M. et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo against Zaire Ebola virus. Antivirus Res. 2014; 10: 1–7. doi:10.1016/j.antiviral.2014.09.0123Garrison A.R., Giomarelli B.G., Lear-Rooney C.M. et al. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo against Zaire Ebola virus. Antivirus Res. 2014; 10: 1–7. doi:10.1016/j.antiviral.2014.09.0123Mitchell C.A., Ramessar K., O’Keefe B.R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Research. 2017; 142: 37–54. doi:10.1016/j.antiviral.2017.03.007Mitchell C.A., Ramessar K., O’Keefe B.R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Research. 2017; 142: 37–54. doi:10.1016/j.antiviral.2017.03.007Liu J., ObaidiI., Nagar S. et al. The antiviral potential of algal-derived macromolecules. 2021; 3: 120–134. doi:10.1016/j.crbiot.2021.04.003Liu J., ObaidiI., Nagar S. et al. The antiviral potential of algal-derived macromolecules. 2021; 3: 120–134. doi:10.1016/j.crbiot.2021.04.003Карамов Э.В., Горбачева А.П., Корнилаева Г.В., Лукьянова Н.С., Пашкова Т.А., Щелканов М.Ю., Ярославцева Н.Г. Изучение молекулярных механизмов вирусиндуцированного слияния мембран. Информационный бюллетень Российского фонда фундаментальных исследований. 1995; 3 (4): 361.Karamov E.V., Gorbacheva A.P., Kornilaeva G.V. et al. Study of the molecular mechanisms of virus-induced membrane fusion. Informatsionnyy byulleten' Rossiyskogo Fonda Fundamental'nykh Issledovaniy. 1995; 3 (4): 361. (in Russian)Shchelkanov M.Yu., Yudin A.N., Antonov A.V. et al. Variability Analysis of HIV-1 gp120 V3 Region: I. Point Estimators for the Amino Acid Distribution Characteristics. Journal of Biomolecular Structure and Dynamics. 1997 a; 15 (2): 217–229. doi:10.1080/07391102.1997.10508187Shchelkanov M.Yu., Yudin A.N., Antonov A.V. et al. Variability Analysis of HIV-1 gp120 V3 Region: I. Point Estimators for the Amino Acid Distribution Characteristics. Journal of Biomolecular Structure and Dynamics. 1997 a; 15 (2): 217–229. doi:10.1080/07391102.1997.10508187Coulibaly F.S., Thomas D.N., Youan B-B. Anti HIV lectins and current delivery strategies. AIMS Molecular Science. 2018; 5 (1): 96–116. doi:10.3934/molsci.2018.1.96.Coulibaly F.S., Thomas D.N., Youan B-B. Anti HIV lectins and current delivery strategies. AIMS Molecular Science. 2018; 5 (1): 96–116. doi:10.3934/molsci.2018.1.96.Karamov E.V., Yaroslavtseva N.G., Shchelkanov M.Yu. et al. Antigenic and genetic relations between different HIV-1 subtypes in Russia. Immunology and Infectious Diseases. 1996; 6: 15–24. (In Russ.).Karamov E.V., Yaroslavtseva N.G., Shchelkanov M.Yu. et al. Antigenic and genetic relations between different HIV-1 subtypes in Russia. Immunology and Infectious Diseases. 1996; 6: 15–24. (In Russ.).Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS. 2019; 14 (3): 153-160. doi:10.1097/COH.0000000000000534Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS. 2019; 14 (3): 153-160. doi:10.1097/COH.0000000000000534Shchelkanov M.Yu., Yudin A.N., Antonov A.V. et al. Variability Analysis of HIV-1 gp120 V3 Region: II. Hierarchy of taxons. Journal of Biomolecular Structure and Dynamics. 1997 b; 15 (2): 231–241. doi:10.1080/07391102.1997.10508188Shchelkanov M.Yu., Yudin A.N., Antonov A.V. et al. Variability Analysis of HIV-1 gp120 V3 Region: II. Hierarchy of taxons. Journal of Biomolecular Structure and Dynamics. 1997 b; 15 (2): 231–241. doi:10.1080/07391102.1997.10508188Martin-Moreno A., Munoz-Fernandez A. Dendritic cells, the double agent in the war against HIV-1. Front. Immunol. 2019. doi:10.3389/fimmu.2019.02485.Martin-Moreno A., Munoz-Fernandez A. Dendritic cells, the double agent in the war against HIV-1. Front. Immunol. 2019. doi:10.3389/fimmu.2019.02485.Esser M.T., Mori T., Mondor I. et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 1999; 73: 4360–4371.Esser M.T., Mori T., Mondor I. et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 1999; 73: 4360–4371.Buffa V., Stieh D., Mamhood N. et al. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J. Gen. Virol. 2009; 90: 234–243. doi:10.1099/vir.0.004358-0Buffa V., Stieh D., Mamhood N. et al. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J. Gen. Virol. 2009; 90: 234–243. doi:10.1099/vir.0.004358-0Щелканов М.Ю., Ярославцева Н.Г., Емельянов А.В., Сахурия И.Б., Абэлян А.В., Верёвочкин С.В., Козлов А.П., Карамов Э.В. Модель функционирования верхушечного эпитопа V3-петли gp120 ВИЧ-1 в составе комплекса с антителами. Молекулярная биология. 1998; 32 (6): 1062–1074.Shchelkanov M.Yu., Yaroslavtseva N.G., Emelyanov A.V. et al. Model of functioning of the apical epitope of the HIV-1 gp120 V3-loop as part of a complex with antibodies. Molekulyarnaya Biologiya. 1998; 32 (6): 1062–1074. (in Russian)Obiero J.P, Ogongo P., Mwethera C., Wiysonge S. Микробициды для местного применения для профилактики инфекций, передающихся половым путем. Cochrane Database of Systematic Reviews. 2021. doi:10.1002/14651858.CD007961.pub3Obiero J.P, Ogongo P., Mwethera C., Wiysonge S. Микробициды для местного применения для профилактики инфекций, передающихся половым путем. Cochrane Database of Systematic Reviews. 2021. doi:10.1002/14651858.CD007961.pub3Жернов Ю.В., Хаитов М.Р. Микробициды для топической иммунопрофилактики ВИЧ-инфекции. Бюлл. Сибирской медицины. 2019; 18 (1): 49–59. https://doi.org/10.20538/1682-0363-2019-1-49-59.Zhernov Yu.V., Khaitov M.R. Microbicides for topical immunoprophylaxis of HIV infection. Byulleten' Sibirskoy Meditsiny. 2019; 18 (1): 49–59. https://doi.org/10.20538/1682-0363-2019-1-49-59. (in Russian)Boyd M.R., Gustafson K.R., McMahon J.B. et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob agent Chemother. 1997; 41: 1521–1530.Boyd M.R., Gustafson K.R., McMahon J.B. et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob agent Chemother. 1997; 41: 1521–1530.Pagarete A., Ramos A.S., Puntervoll P. et al. Antiviral potential of algal metabolites – a comprehensive review. Mar. Drugs. 2021; 19 (2): 94. doi:10.3390/md19020094Pagarete A., Ramos A.S., Puntervoll P. et al. Antiviral potential of algal metabolites – a comprehensive review. Mar. Drugs. 2021; 19 (2): 94. doi:10.3390/md19020094Tsai C-C., Emau P., Jiang Y. et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. And Human Retroviruses 2004; 20 (1). doi:10.1089/088922204322749459.Tsai C-C., Emau P., Jiang Y. et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. And Human Retroviruses 2004; 20 (1). doi:10.1089/088922204322749459.Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 2006; 7 (2–3): 237–247. doi:10.1016/j.antiviral.2006.02.004.Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 2006; 7 (2–3): 237–247. doi:10.1016/j.antiviral.2006.02.004.Huskens D., Vermeire K., Vandemeulebroucke E., Balzarini J., Schols D. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int. J. Biochem. 2008; 40 (12): 2804–28014. doi:10.1016/j.biocel.2008.05.023.Huskens D., Vermeire K., Vandemeulebroucke E., Balzarini J., Schols D. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int. J. Biochem. 2008; 40 (12): 2804–28014. doi:10.1016/j.biocel.2008.05.023.Chen J., Huang D. Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 targeting the glycan ligand. PLoS One. 2014; 9 (1): e86455. doi:10.1371/journal.pone.0086455.Chen J., Huang D. Linker-extended native cyanovirin-N facilitates PEGylation and potently inhibits HIV-1 targeting the glycan ligand. PLoS One. 2014; 9 (1): e86455. doi:10.1371/journal.pone.0086455.Akkouh O., Ng T.B., Singh S.S. et al. Lectins with anti-HIV activity: a review. Molecules. 2015; 6 (20): 648–668. doi:10.3390/molecules20010648.Akkouh O., Ng T.B., Singh S.S. et al. Lectins with anti-HIV activity: a review. Molecules. 2015; 6 (20): 648–668. doi:10.3390/molecules20010648.Huskens D., Ferir K., Vermeire J. et al. Microvirin, a novel α (1,20-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV1 activity comparable with than of cyanovirin-N but a much higher safety profile. Microbiology. 2010; 285 (32): 24845–24854. doi:10.1074/jbc.M110.128546.Huskens D., Ferir K., Vermeire J. et al. Microvirin, a novel α (1,20-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV1 activity comparable with than of cyanovirin-N but a much higher safety profile. Microbiology. 2010; 285 (32): 24845–24854. doi:10.1074/jbc.M110.128546.Shahid M., Qadir A., Yang J. et al. An engineered microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry. Viruses. 2020; 12 (2): 199. doi:10.3390/v12020199.Shahid M., Qadir A., Yang J. et al. An engineered microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry. Viruses. 2020; 12 (2): 199. doi:10.3390/v12020199.Lagenaur L.A., Swedek I., Lee P.P., Parks T.P. Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women. PLoS One. 2015; 10 (4): e0122730. doi:10.1371/journal.pone.0122730.Lagenaur L.A., Swedek I., Lee P.P., Parks T.P. Robust vaginal colonization of macaques with a novel vaginally disintegrating tablet containing a live biotherapeutic product to prevent HIV infection in women. PLoS One. 2015; 10 (4): e0122730. doi:10.1371/journal.pone.0122730.Lofti H., Sheervalilo R., Zarghami N. An update of the recombinant protein expression systems of cyanovirin-N and challenges of preclinical development. Bioimpacts. 2018; 8: 139–151. doi:10.15171/bi.2018.16.Lofti H., Sheervalilo R., Zarghami N. An update of the recombinant protein expression systems of cyanovirin-N and challenges of preclinical development. Bioimpacts. 2018; 8: 139–151. doi:10.15171/bi.2018.16.Madeira L.M., Szeto T.H., Ma J.K-C., Drake P.M.W. Rhizosecretion improves the production of cyanovirin-N in Nicotiana tabacum through simplified downstream processing. Biotechnol. J. 2016; 11 (7): 910–919. doi:10.1002/biot.201500371.Madeira L.M., Szeto T.H., Ma J.K-C., Drake P.M.W. Rhizosecretion improves the production of cyanovirin-N in Nicotiana tabacum through simplified downstream processing. Biotechnol. J. 2016; 11 (7): 910–919. doi:10.1002/biot.201500371.J’Keefe B.R., Murad A.M., Vianna G.R. et al. Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV. Plant Biotechnol. J. 2015; 13: 884–892.J’Keefe B.R., Murad A.M., Vianna G.R. et al. Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV. Plant Biotechnol. J. 2015; 13: 884–892.Armario-Najera V., Blanco-Perera A, Shenoy S.R. et al. Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1. Plant Cell Reports. 2022; 41: 1013–1023.Armario-Najera V., Blanco-Perera A, Shenoy S.R. et al. Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1. Plant Cell Reports. 2022; 41: 1013–1023.Рахманова А.Г., Яковлев А.А., Кащенко В.А., Шаройко В.В. Хронический вирусный гепатит С и цирроз печени. Руководство для врачей. С-Пб.: СпецЛит. 2016; 380.Rakhmanova A.G., Yakovlev A.A., Kashchenko V.A., Sharoiko V.V. Chronic viral hepatitis C and cirrhosis of the liver. Guide for doctors. S-Pb.: SpecialLit. 2016; 380. (in Russian)Kim C.W., Chang K.M. Hepatitis C virus: virology and life cycle. Clin. Mol. Hepatol 2013; 19: 17–125.Kim C.W., Chang K.M. Hepatitis C virus: virology and life cycle. Clin. Mol. Hepatol 2013; 19: 17–125.Соколова Т.М. Вирус гепатита С (Flaviviridae: Hepacivirus C): регуляция сигнальных реакций врожденного иммунитета. Вопросы вирусологии. 2020; 65 (6): 307–1316. https://doi.org/10.36233/0507-4088-2020-65-6-1.Sokolova T.M. Virus gepatita S (Flaviviridae: Hepacivirus C): regulyatsiya signal'nykh reaktsij vrozhdennogo immuniteta. Voprosy virusologii. 2020; 65 (6): 307–1316. https://doi.org/10.36233/0507-4088-2020-65-6-1. (in Russian)Benedicto I., Gondar V., Molina-Jimenez J. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2015; 89: 4180–4190.Benedicto I., Gondar V., Molina-Jimenez J. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J. Virol. 2015; 89: 4180–4190.Krey T., Alayer J., Kikuti C.M. et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010: e10000762.Krey T., Alayer J., Kikuti C.M. et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010: e10000762.Guo Y., Yu H., Zhong Y. et al. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. Medicine. 2018; 97 (15): e0208. doi:10.1097/MD.0000000000010208.Guo Y., Yu H., Zhong Y. et al. Lectin microarray and mass spectrometric analysis of hepatitis C proteins reveals N-linked glycosylation. Medicine. 2018; 97 (15): e0208. doi:10.1097/MD.0000000000010208.Kachko A., Loesgen S., Shazad-Ul-Hussan S. et al. Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol. Pharm. 2013; 10 (12): 4590–4602. doi:10.1021/mp400399b.Kachko A., Loesgen S., Shazad-Ul-Hussan S. et al. Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol. Pharm. 2013; 10 (12): 4590–4602. doi:10.1021/mp400399b.Ito S., Ikuno T., Mishima et al. In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. J. of Immunotoxicology. 2019; 16: 125-132.Ito S., Ikuno T., Mishima et al. In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. J. of Immunotoxicology. 2019; 16: 125-132.Min Y.Q., Duan X-C., Zhou Y-D. Effects of microvirin monomers and oligomers on hepatitis C virus. Bioscience Reports. 2017; 37 BSR20170015. doi:10.1042/BSR20170015.Min Y.Q., Duan X-C., Zhou Y-D. Effects of microvirin monomers and oligomers on hepatitis C virus. Bioscience Reports. 2017; 37 BSR20170015. doi:10.1042/BSR20170015.Takebe Y., Saucedo C.J., Lund G. et al. Antiviral lectins from red and bluegreen algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One. 2013; 8 (5): e64449. doi:10.1371/journal.pone.0064449.Takebe Y., Saucedo C.J., Lund G. et al. Antiviral lectins from red and bluegreen algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One. 2013; 8 (5): e64449. doi:10.1371/journal.pone.0064449.Carpine R., Sieber S. Antibacterial and antiviral metabolites from cyanobacteria: their application and their impact on human health. Current Research in Biotechnology. 2021; 3: 65–81. doi:10.1016/j.crbiot.2021.03.001.Carpine R., Sieber S. Antibacterial and antiviral metabolites from cyanobacteria: their application and their impact on human health. Current Research in Biotechnology. 2021; 3: 65–81. doi:10.1016/j.crbiot.2021.03.001.Izquierdo L., Oliveira C., Fournier C. et al. Hepatitis C virus resistance to carbohydrate-binding agents. PLoS ONE 2016; 11 (2): e0149064. doi:10.1371/journal.pone.0149064.Izquierdo L., Oliveira C., Fournier C. et al. Hepatitis C virus resistance to carbohydrate-binding agents. PLoS ONE 2016; 11 (2): e0149064. doi:10.1371/journal.pone.0149064.Murphy P.V., André S., Gabius H.J. The third dimension of reading the sugar code by lectins: design of glycoclusters with cyclic scaffolds as tools with the aim to define correlations between spatial presentation and activity. Molecules. 2013; 18: 4026–4053. doi:10.3390/molecules18044026Murphy P.V., André S., Gabius H.J. The third dimension of reading the sugar code by lectins: design of glycoclusters with cyclic scaffolds as tools with the aim to define correlations between spatial presentation and activity. Molecules. 2013; 18: 4026–4053. doi:10.3390/molecules18044026Kaltner H., Gabius H.J. A toolbox of lectins for translating the sugar code: the galectin network in phylogenesis and tumors. Histol Histopathol. 2012; 27: 397–416. doi:10.14670/hh-27.397Kaltner H., Gabius H.J. A toolbox of lectins for translating the sugar code: the galectin network in phylogenesis and tumors. Histol Histopathol. 2012; 27: 397–416. doi:10.14670/hh-27.397Saad A.A. Recombinant lectins as pioneering anti-viral agents against COVID-19. Hematol. Transfus. Int. J. 2021; 9 (4): 77–79. doi:10.15406/htij.2021.09.00259Saad A.A. Recombinant lectins as pioneering anti-viral agents against COVID-19. Hematol. Transfus. Int. J. 2021; 9 (4): 77–79. doi:10.15406/htij.2021.09.00259Swanson M.D., Boudreaux D.M., Salmon L. et al. Engineering therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell. 2015; 163 (3): 746–758. doi:10.1016/j.cell.2015.09.058.Swanson M.D., Boudreaux D.M., Salmon L. et al. Engineering therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell. 2015; 163 (3): 746–758. doi:10.1016/j.cell.2015.09.058.Coves-Datson E.M. Dyall J., DeWald L.E. et al. Inhibition of Ebola virus by molecularly engineered banana lectin. PLoS Negl. Trop. Dis. 2019; 13: e0007595;Coves-Datson E.M. Dyall J., DeWald L.E. et al. Inhibition of Ebola virus by molecularly engineered banana lectin. PLoS Negl. Trop. Dis. 2019; 13: e0007595;Coves-Datsdon E.M., King S.R. Legendre M. et al. A molecvularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. Proc. Natl. Acad. Sci. USA. 2020; 117 (4): 2122–2132. doi:10.1073/pnas.1915152117.Coves-Datsdon E.M., King S.R. Legendre M. et al. A molecvularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. Proc. Natl. Acad. Sci. USA. 2020; 117 (4): 2122–2132. doi:10.1073/pnas.1915152117.Konozy E., Osman M., Dirar A. Plant lectins as potent anti-coronaviruses, anti-inflammatory, antinoceptive and antiulcer agents. Saudi J. of Biological Sciences. 2022; 29 (6): 103301. doi:/10.1016/j.sjbs.2022.103301.Konozy E., Osman M., Dirar A. Plant lectins as potent anti-coronaviruses, anti-inflammatory, antinoceptive and antiulcer agents. Saudi J. of Biological Sciences. 2022; 29 (6): 103301. doi:/10.1016/j.sjbs.2022.103301.Encarnacao T., Pais A.C.C., Campos M.G. et al. Cyanobacteria and microalgae: a renewable source of bioactive compounds and other chemicals. Science Progress. Research Article. 2015. doi:10.3184/003685015X14298590596266Encarnacao T., Pais A.C.C., Campos M.G. et al. Cyanobacteria and microalgae: a renewable source of bioactive compounds and other chemicals. Science Progress. Research Article. 2015. doi:10.3184/003685015X14298590596266Pradhan B., Nayak R., Patra S. et al. Cyanobacteria and algae-derived bioactive metabolites as antiviral agents: evidence, mode of action, and scope for furth expansion; a comprehensive review in light of the SARSCoV-2 outbreak. Antioxidants/ 2022-02-11, doi:10.3390/antiox11020354.Pradhan B., Nayak R., Patra S. et al. Cyanobacteria and algae-derived bioactive metabolites as antiviral agents: evidence, mode of action, and scope for furth expansion; a comprehensive review in light of the SARSCoV-2 outbreak. Antioxidants/ 2022-02-11, doi:10.3390/antiox11020354.

The authors declare that there are no conflicts of interest present.